{"version":"1.0","type":"link","title":"Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer.","author_name":"Matsumoto M 외","author_url":"https://prs-insight.online/author/Matsumoto%20M","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/169115","thumbnail_width":1200,"thumbnail_height":630}